EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction

Jianan Lv, Dan Zhu, Sisi Song, Jiahui Zhou, Xiaoyu Zhang, Wenhua Zhou, Yu Liu iD, Zizhen Si

Addiction Biology · 2026-04 · 31 (4)

DOI: 10.1111/adb.70152 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Addiction Biology, online erschienen am 14.04.2026. Verfasst von Jianan Lv und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Health Science Center, Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Receptor, Angiotensin, Type 1, Central Nervous System Diseases, Substance-Related Disorders, Behavior, Addictive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Young Doctor Innovation Research Program of Ningbo, Ningbo Public Welfare Research Program Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the angiotensin II type 1 receptor (AT1R), a pivotal component of the renin–angiotensin system (RAS), is associated with cardiovascular and renal homeostasis, burgeoning evidence implicates its critical role in neuropsychiatric disorders, particularly addiction. Beyond regulating haemodynamics, AT1R activation in the central nervous system (CNS) modulates neuroinflammatory cascades, dopaminergic signalling plasticity, and stress‐responsive neural circuit processes central to addiction pathophysiology. Notably, preclinical studies reveal that AT1R blockade attenuates drug‐seeking behaviours by normalizing mesolimbic dopamine dysregulation and reducing glutamatergic excitotoxicity in the nucleus accumbens. This review systematically integrates contemporary evidence elucidating the dual pathophysiological roles of AT1R in CNS disorders, with particular emphasis on neurodegenerative diseases and psychiatric conditions. Crucially, we delineate two mechanistically distinct yet interconnected functions of AT1R: (1) serving as a critical mediator of maladaptive neuroplasticity during protracted exposure to addictive substances and (2) functioning as a regulator of blood–brain barrier (BBB) integrity, thereby potentiating neurotoxicant infiltration in substance use disorders. Building upon these mechanistic insights, we propose a translational framework for repurposing clinically approved AT1R antagonists as novel pharmacotherapies targeting addiction‐related neurocircuitry dysregulation. By bridging molecular insights with translational opportunities, this work positions AT1R as a novel therapeutic target to address unmet clinical needs in addiction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Angiotensin, Type 1Central Nervous System DiseasesSubstance-Related DisordersBehavior, AddictiveHumansAnimalsNeuronal PlasticityBlood-Brain BarrierAngiotensin II Type 1 Receptor BlockersRenin-Angiotensin SystemMesolimbic SystemDopamine

Stichwörter der Autor:innen

angiotensin II type 1 receptorneuropsychiatric disorderspsychostimulantssubstance use disorderstherapeutic target

Substanzen

Receptor, Angiotensin, Type 1Angiotensin II Type 1 Receptor BlockersDopamine

Autor:innen und Institutionen

  • School of Pharmacy, Health Science Center, Ningbo University, Ningbo, China.
  • School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
  • Department of Psychology, Collage of Teacher Education, Ningbo University, Ningbo, China.
  • Zhejiang Provincial Key Laboratory of Addiction Research, The Affiliated Kangning Hospital of Ningbo University, Ningbo, China.

ORCID-Profile: Yu Liu

Förderung

  • National Natural Science Foundation of China
  • Young Doctor Innovation Research Program of Ningbo
  • Ningbo Public Welfare Research Program Project
  • Li Dasan and Ye Yaozhen Couple Li Benjun Marine Biomedicine R&D Fund of Ningbo University
  • Ningbo Yongjiang 2035 Research Project

Zitieren

APA

Lv, J., Zhu, D., Song, S., Zhou, J., Zhang, X., Zhou, W., Liu, Y., & Si, Z. (2026). AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction. Addiction Biology, 31(4). https://doi.org/10.1111/adb.70152

Vancouver

Lv J, Zhu D, Song S, Zhou J, Zhang X, Zhou W, et al. AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction. Addiction Biology. 2026;31(4). doi:10.1111/adb.70152

BibTeX
@article{Lv2026,
  author = {Lv, Jianan and Zhu, Dan and Song, Sisi and Zhou, Jiahui and Zhang, Xiaoyu and Zhou, Wenhua and Liu, Yu and Si, Zizhen},
  title = {AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction},
  journal = {Addiction Biology},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.1111/adb.70152}
}
Kostenlos starten →